- Home
- COLL vs THQ Comparison
COLL vs THQ Comparison
Compare COLL & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- THQ
- Stock Information
- Founded
- COLL 2002
- THQ 2014
- Country
- COLL United States
- THQ United States
- Employees
- COLL N/A
- THQ N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- THQ Finance Companies
- Sector
- COLL Health Care
- THQ Finance
- Exchange
- COLL Nasdaq
- THQ Nasdaq
- Market Cap
- COLL 910.2M
- THQ 845.7M
- IPO Year
- COLL 2015
- THQ N/A
- Fundamental
- Price
- COLL $25.95
- THQ $18.23
- Analyst Decision
- COLL Strong Buy
- THQ
- Analyst Count
- COLL 5
- THQ 0
- Target Price
- COLL $43.60
- THQ N/A
- AVG Volume (30 Days)
- COLL 449.2K
- THQ 158.9K
- Earning Date
- COLL 05-08-2025
- THQ 01-01-0001
- Dividend Yield
- COLL N/A
- THQ 7.53%
- EPS Growth
- COLL 43.56
- THQ N/A
- EPS
- COLL 1.86
- THQ N/A
- Revenue
- COLL $631,449,000.00
- THQ N/A
- Revenue This Year
- COLL $20.00
- THQ N/A
- Revenue Next Year
- COLL $3.93
- THQ N/A
- P/E Ratio
- COLL $14.75
- THQ N/A
- Revenue Growth
- COLL 11.41
- THQ N/A
- 52 Week Low
- COLL $26.64
- THQ $15.29
- 52 Week High
- COLL $42.29
- THQ $20.38
- Technical
- Relative Strength Index (RSI)
- COLL 36.45
- THQ 33.50
- Support Level
- COLL $26.64
- THQ $17.42
- Resistance Level
- COLL $28.37
- THQ $20.50
- Average True Range (ATR)
- COLL 0.93
- THQ 0.52
- MACD
- COLL -0.23
- THQ -0.25
- Stochastic Oscillator
- COLL 25.10
- THQ 33.15
Stock Price Comparison Chart: COLL vs THQ
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.